L Chi

Summary

Affiliation: Parke-Davis Pharmaceutical Research
Country: USA

Publications

  1. ncbi request reprint Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran
    L Chi
    Cardiovascular Therapeutics Section, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    J Thromb Thrombolysis 11:19-31. 2001
  2. ncbi request reprint A novel model of venous thrombosis in the vena cava of rabbits
    L Chi
    Vascular and Cardiac Diseases Section, Parke Davis Pharmaceutical Research Division, Ann Arbor, Michigan 48105 USA
    J Pharmacol Toxicol Methods 39:193-202. 1998
  3. ncbi request reprint Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
    K L Rogers
    Department of Pharmacokinetics, Dynamics and Metabolism, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, MI 48105, USA
    Basic Res Cardiol 94:15-22. 1999
  4. ncbi request reprint Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors
    D A Dudley
    Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 43:4063-70. 2000
  5. ncbi request reprint Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro
    W R Gould
    Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, MI 48105, USA
    J Thromb Haemost 4:834-41. 2006
  6. ncbi request reprint Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits
    L Chi
    Pfizer Global R and D, Ann Arbor Laboratories, Cardiovascular Pharmacology, Ann Arbor, MI 48105, USA
    J Thromb Haemost 2:85-92. 2004
  7. ncbi request reprint Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors
    A R Porcari
    Information Research and Analysis, Department of Knowledge Management Services, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    Expert Opin Investig Drugs 9:1595-600. 2000
  8. ncbi request reprint Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases
    R J Leadley
    Pfizer Global Research and Development, Ann Arbor, MI 48105, USA
    Curr Opin Pharmacol 1:169-75. 2001

Detail Information

Publications8

  1. ncbi request reprint Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran
    L Chi
    Cardiovascular Therapeutics Section, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan 48105, USA
    J Thromb Thrombolysis 11:19-31. 2001
    ..These results indicate that LB-30057 is an effective antithrombotic compound and it appears to have a better benefit/risk profile than inogatran in this experimental model...
  2. ncbi request reprint A novel model of venous thrombosis in the vena cava of rabbits
    L Chi
    Vascular and Cardiac Diseases Section, Parke Davis Pharmaceutical Research Division, Ann Arbor, Michigan 48105 USA
    J Pharmacol Toxicol Methods 39:193-202. 1998
    ....
  3. ncbi request reprint Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis
    K L Rogers
    Department of Pharmacokinetics, Dynamics and Metabolism, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, MI 48105, USA
    Basic Res Cardiol 94:15-22. 1999
    ....
  4. ncbi request reprint Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors
    D A Dudley
    Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 43:4063-70. 2000
    ..This compound exhibited high selectivity for FXa over other related serine proteases and was efficacious when dosed intravenously in rabbit and dog antithrombotic models...
  5. ncbi request reprint Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro
    W R Gould
    Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, MI 48105, USA
    J Thromb Haemost 4:834-41. 2006
    ..Many compounds currently in development for treatment of thrombotic disorders demonstrate high specificity for single targets of blood coagulation such as factor Xa (FXa) or thrombin...
  6. ncbi request reprint Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits
    L Chi
    Pfizer Global R and D, Ann Arbor Laboratories, Cardiovascular Pharmacology, Ann Arbor, MI 48105, USA
    J Thromb Haemost 2:85-92. 2004
    ..This model may be useful for evaluating in vivo efficacy of new antithrombotic drugs, particularly TF-FVIIa inhibitors...
  7. ncbi request reprint Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors
    A R Porcari
    Information Research and Analysis, Department of Knowledge Management Services, Parke Davis Pharmaceutical Research Division, Warner Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    Expert Opin Investig Drugs 9:1595-600. 2000
    ..The purpose of this review is to compile and summarise the published Phase I and II clinical data for SR90107A/ORG31540 and DX-9065a...
  8. ncbi request reprint Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases
    R J Leadley
    Pfizer Global Research and Development, Ann Arbor, MI 48105, USA
    Curr Opin Pharmacol 1:169-75. 2001
    ....